Supplementation of iron in pulmonary hypertension: Rationale and design of a phase ii clinical trial in idiopathic pulmonary arterial hypertension

Pulmonary Circulation

Volumn 3, Issue 1, 2013, Pages 100-107

  Howard, Luke S G E ^a,b   Watson, Geoffrey M J ^c   Wharton, John ^c   Rhodes, Christopher J ^c   Chan, Kakit ^h   Khengar, Rajeshree ^d   Robbins, Peter A ^e   Kiely, David G ^f   Condliffe, Robin ^f   Elliott, Charlie A ^f   Pepke Zaba, Joanna ^g   Sheares, Karen ^g   Morrell, Nicholas W ^g   Davies, Rachel ^a   Ashby, Deborah ^h   Gibbs, J Simon R ^a,b   Wilkins, Martin R ^c  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^g PAPWORTH HOSPITAL   (United Kingdom)

^h IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Exercise capacity; Ferric carboxymaltose; Iron; Pulmonary arterial hypertension; Pulmonary vascular resistance

Indexed keywords

EID: 84918831608     PISSN: 20458932     EISSN: 20458940     Source Type: Journal    
DOI: 10.4103/2045-8932.109923     Document Type: Article

References (25)

1. Weiss G. Iron metabolism in the anemia of chronic disease. Biochim Biophys Acta 2009;1790:682-93.
2. Rhodes CJ, Howard LS, Busbridge M, Ashby D, Kondili E, Gibbs JS, et al. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: Clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol 2011;58:300-9.
3. Ruiter G, Lankhorst S, Boonstra A, Postmus PE, Zweegaman S, Westerhof N, et al. Iron deficiency is common in idiopathic pulmonary arterial hypertension. Eur Respir J 2011;37:1386-91.
4. Soon E, Treacy CM, Toshner MR, MacKenzie-Ross R, Manglam V, Busbridge M, et al. Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension. Thorax 2011;66:326-32.
5. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005;352:1011-23.
6. Cook JD, Dassenko S, Skikne BS. Serum transferrin receptor as an index of iron absorption. Br J Haematol 1990;75:603-9.
7. Zhu YI, Haas JD. Altered metabolic response of iron-depleted nonanemic women during a 15-km time trial. J Appl Physiol 1998;84:1768-75.
8. Brownlie T, Utermohlen V, Hinton PS, Haas JD. Tissue iron deficiency without anemia impairs adaptation in endurance capacity after aerobic training in previously untrained women. Am J Clin Nutr 2004;79:437-43.
9. Jankowska EA, Rozentryt P, Witkowska A, Nowak J, Hartmann O, Ponikowska B, et al. Iron deficiency: An ominous sign in patients with systolic chronic heart failure. Eur Heart J 2010;31:1872-80.
10. Okonko DO, Grzeslo A, Witkowski T, Mandal AK, Slater RM, Roughton M, et al. Effect of intravenous iron sucrose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF: A randomized, controlled, observer-blinded trial. J Am Coll Cardiol 2008;51:103-12.
11. Anker SD, Comin CJ, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-48.
12. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al. ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537.
13. American Thoracic Society; American College of Chest Physicians. ATS/ACCP Statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003;167:211-77.
14. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-7.
15. McKenna SP, Doughty N, Meads DM, Doward LC, Pepke-Zaba J. The Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR): A measure of health-related quality of life and quality of life for patients with pulmonary hypertension. Qual Life Res 2006;15:103-15.
16. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: A randomised placebo-controlled study. Lancet 2001;358:1119-23.
17. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9.
18. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57.
19. Rhodes CJ, Wharton J, Howard L, Gibbs JS, Vonk-Noordegraaf A, Wilkins MR. Iron deficiency in pulmonary arterial hypertension: A potential therapeutic target. Eur Respir J 2011;38:1453-60.
20. Smith TG, Balanos GM, Croft QP, Talbot NP, Dorrington KL, Ratcliffe PJ, et al. The increase in pulmonary arterial pressure caused by hypoxia depends on iron status. J Physiol 2008;586:5999-6005.
21. Smith TG, Talbot NP, Privat C, Rivera-Ch M, Nickol AH, Ratcliffe PJ, et al. Effects of iron supplementation and depletion on hypoxic pulmonary hypertension: Two randomized controlled trials. JAMA 2009; 302:1444-50.
22. Wong CM, Preston IR, Hill NS, Suzuki YJ. Iron chelation inhibits the development of pulmonary vascular remodelling. Free Radic Biol Med 2012;53:1738-47.
23. Park AM, Wong CM, Jelinkova L, Liu L, Nagase H, Suzuki YJ. Pulmonary hypertension-induced GATA4 activation in the right ventricle. Hypertension 2010;56:1145-51.
24. Kaemmerer H, Fratz S, Braun SL, Koelling K, Eicken A, Brodherr-Heverlein S, et al. Erythrocyte indexes, iron metabolism, and hyperhomocysteinemia in adults with cyanotic congenital cardiac disease. Am J Cardiol 2004;94:825-8.
25. Tay EL, Peset A, Papaphylactou M, Inzuka R, Alonso-Gonzalea R, Giannakoulas G, et al. Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome. Int J Cardiol 2011;151:307-12.